Record $52.3m profit as portfolio returned 37.6%, beating benchmark by 9.5pp

The portfolio delivered a total return of 37.6%, 9.5 percentage points ahead of the benchmark's 28.1% (which itself rebounded sharply from a -6.6% prior year). NTA per share rose 27.9% to 87.0c, and net assets attributable to shareholders grew 31.2% to $185.7m.

Underneath the headline, the composition is more mixed. Investment income (dividends and interest) declined 6.5% to $2.9m, while investment total return — which includes realised and unrealised gains — rose to $57.2m from $15.7m. PBT grew 307.1% and NPAT grew 318.4%, with the 11.3pp gap reflecting a small tax credit (effective rate -1.2% versus +1.1% prior) rather than an operating signal.

• The 9.5pp benchmark beat (37.6% vs 28.1%) is the genuinely durable analytical signal here, because it isolates manager skill from market beta. ROE of 28.2% versus 8.8% prior is the same story expressed at the equity-return level, but a single year of outperformance against a sharply recovering benchmark is not yet a trend.

• Distribution coverage on a recurring-income basis remains low. Distribution coverage came in at 40.5% versus 43.5% prior — meaning realised investment income covers under half of distributions paid, with the balance funded from capital. The full-year distribution of 6.0c per share is consistent with the company's published policy of paying a percentage of NAV, but the gap between income generation and cash returned to shareholders is what makes the policy capital-dependent rather than income-funded.

• The income line is shrinking, not growing. Investment income fell 6.5% year on year even as portfolio value rose. For a listed investment company, that widens the structural gap between distributable income and the headline profit number, and makes future distribution levels more sensitive to portfolio composition and realised-gains timing.

The HY21 context shows the first half captured roughly 60% of full-year investment income and NPAT — implying a softer second half in absolute terms ($20.7m H2 NPAT versus $31.6m H1) as market gains moderated.

What the release supports is that FY21 captured a strong post-pandemic rebound year. What it does not support is a base-case expectation that 37.6% portfolio returns or 318.4% NPAT growth repeat; both are leveraged to market direction and the unusually weak benchmark comparable.

Of the $57.2m investment total return, only about $2.9m is recurring dividend and interest income; the remainder is realised and unrealised gains on equities, which are mark-to-market and reverse with markets. That is the appropriate frame for a listed investment vehicle, but it means the "record profit" headline is more a statement about NZX growth-equity performance than about a step-change in the underlying earnings engine.

Operating cash inflow of $6.7m (versus a $10.6m outflow prior) and net assets growth of 31.2% to $185.7m are genuine and balance-sheet-supported. The tax credit narrowing PBT-to-NPAT (effective rate -1.2%) and the small cash balance of $0.9m versus $2.4m prior are presentational rather than economically material at this scale. The expense ratio is not disclosed in this release, which limits any read on cost discipline relative to net assets.

This briefing cannot assess whether the 9.5pp benchmark outperformance reflects repeatable manager skill or single-period stock selection, because no multi-year attribution or holdings-level disclosure is provided in the release.